Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRD-TMH-001 in Duchenne Muscular Dystrophy
NCT05514249Phase 1Completed
- Sponsor
- Cure Rare Disease
- Start
- Aug 2022
- Primary completion
- Oct 2022
- Modality
- CRISPR-Cas9, Gene Silencing, Gene Addition/Replacement
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CRD-TMH-001 in Duchenne muscular dystrophy (DMD), sponsored by Cure Rare Disease. Primary endpoint: Safety of CRD-TMH-001 at 1 year. Started Aug 2022; status: completed.
02
Drugs
CRD-TMH-001
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT05514249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05514249.